Division of Miraca Holdings Inc.
Latest From SRL Inc.
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Miraca Holdings Inc.
- Senior Management
K. Fujita, MD, PhD, Pres. & CEO
K. Kubota, Mgr., Product Planning
H. Tukada, MD, PhD, Dir., R&D
- Contact Info
Phone: (81) 3 3344 6511
Yasudakasai Tachikawa Bldg.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.